FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3106823914> ?p ?o ?g. }

• W3106823914 endingPage "113786" @default.
• W3106823914 startingPage "113786" @default.
• W3106823914 abstract "Pyrazinamide (PZA), Rifampicin (RIF), Isoniazid (ISH) and Ethambutol (ETB) form the core for the treatment of Tuberculosis, today a devastating disease in low-income populations around the world. These drugs are usually administrated by fixed-dose combination (FDC) products, to favour the patient compliance and prevent bacterial resistance. PZA exists in four enantiotropically-related polymorphs (Forms α, δ, β and γ), but only Form α is considered suitable for pharmaceutical products due to its stability and bioavailability properties. The classical approaches to address solid-state (microscopy, X-ray diffraction and calorimetry) shows limitations for quantification of polymorphs in the presence of excipients and other active components, as in the case of FDC tablets. In this work, an overall strategy was developed using near infrared spectroscopy (NIR) coupled to partial least squares regression (PLS) to quantify Form α of PZA in drug substance (raw material) and PZA/RIF/ISH-FDC tablets. For this purpose, two PLS models were constructed, one for drug substance preparing training (n = 30) and validation (n = 18) samples with a ternary composition (Form α/Form δ/Form γ), and other for FDC drug products, also including the appropriate amount of RIF, ISH and the matrix of excipients in order to simulate the environment of PZA/RIF/ISH association. The NIR-PLS models were optimized using a novel smart approach based on radial optimization (full range, 3 L V and MSC-D’ and SNV-D’ as pre-treatment, for raw material and FDC tablets, respectively). During the validation step, both methods showed no bias or systematic errors and yielded satisfactory recoveries (102.5 ± 3.1 % for drug substance and 98.7 ± 1.5 % for FDC tablets). When commercial drug substance was tested, NIR-PLS was able to predict the content of Form α (0.98 ± 0.01 w/w). The model for FDC tablets allowed estimating polymorphic purity in intact (0.984 ± 0.003 w/w), sectioned (0.986 ± 0.002 w/w), and powered (0.985 ± 0.004 w/w) tablets, showing the methodology could be applied to a different stage of the process (i.e premixed-powders or granulates). The suitability of the method was also verified when Form α was satisfactorily analysed in FDC fortified with Form δ and Form γ to reach 0.78, 0.88 and 0.98 w/w, Form α. This strategy results in an excellent alternative to ensure the polymorphic purity of PZA throughout the overall pharmaceutical manufacturing process." @default.
• W3106823914 created "2020-12-07" @default.
• W3106823914 creator A5025830551 @default.
• W3106823914 creator A5036281368 @default.
• W3106823914 creator A5047514402 @default.
• W3106823914 date "2021-02-01" @default.
• W3106823914 modified "2023-10-06" @default.
• W3106823914 title "Tackling quantitative polymorphic analysis through fixed-dose combination tablets production. Pyrazinamide polymorphic assessment" @default.
• W3106823914 cites W1923394711 @default.
• W3106823914 cites W1969105492 @default.
• W3106823914 cites W1972813496 @default.
• W3106823914 cites W2007808016 @default.
• W3106823914 cites W2020991600 @default.
• W3106823914 cites W2021873216 @default.
• W3106823914 cites W2024233657 @default.
• W3106823914 cites W2024296837 @default.
• W3106823914 cites W2028466512 @default.
• W3106823914 cites W2029544602 @default.
• W3106823914 cites W2032621157 @default.
• W3106823914 cites W2035379578 @default.
• W3106823914 cites W2056570578 @default.
• W3106823914 cites W2057515372 @default.
• W3106823914 cites W2093502119 @default.
• W3106823914 cites W2093772555 @default.
• W3106823914 cites W2100458127 @default.
• W3106823914 cites W2104759152 @default.
• W3106823914 cites W2109719233 @default.
• W3106823914 cites W2312383074 @default.
• W3106823914 cites W2339542453 @default.
• W3106823914 cites W2507603215 @default.
• W3106823914 cites W2763270523 @default.
• W3106823914 cites W2801196343 @default.
• W3106823914 cites W2887575560 @default.
• W3106823914 cites W2899886262 @default.
• W3106823914 cites W2902323688 @default.
• W3106823914 cites W2914966085 @default.
• W3106823914 cites W2919689696 @default.
• W3106823914 cites W2944077098 @default.
• W3106823914 cites W2944109438 @default.
• W3106823914 cites W3003790822 @default.
• W3106823914 cites W3008240300 @default.
• W3106823914 doi "https://doi.org/10.1016/j.jpba.2020.113786" @default.
• W3106823914 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33281002" @default.
• W3106823914 hasPublicationYear "2021" @default.
• W3106823914 type Work @default.
• W3106823914 sameAs 3106823914 @default.
• W3106823914 citedByCount "1" @default.
• W3106823914 countsByYear W31068239142022 @default.
• W3106823914 crossrefType "journal-article" @default.
• W3106823914 hasAuthorship W3106823914A5025830551 @default.
• W3106823914 hasAuthorship W3106823914A5036281368 @default.
• W3106823914 hasAuthorship W3106823914A5047514402 @default.
• W3106823914 hasConcept C105795698 @default.
• W3106823914 hasConcept C142724271 @default.
• W3106823914 hasConcept C185592680 @default.
• W3106823914 hasConcept C22354355 @default.
• W3106823914 hasConcept C2776228421 @default.
• W3106823914 hasConcept C2776623344 @default.
• W3106823914 hasConcept C2776967927 @default.
• W3106823914 hasConcept C2778607973 @default.
• W3106823914 hasConcept C2780459521 @default.
• W3106823914 hasConcept C2781069245 @default.
• W3106823914 hasConcept C33923547 @default.
• W3106823914 hasConcept C43617362 @default.
• W3106823914 hasConcept C501593827 @default.
• W3106823914 hasConcept C55493867 @default.
• W3106823914 hasConcept C71924100 @default.
• W3106823914 hasConcept C98274493 @default.
• W3106823914 hasConceptScore W3106823914C105795698 @default.
• W3106823914 hasConceptScore W3106823914C142724271 @default.
• W3106823914 hasConceptScore W3106823914C185592680 @default.
• W3106823914 hasConceptScore W3106823914C22354355 @default.
• W3106823914 hasConceptScore W3106823914C2776228421 @default.
• W3106823914 hasConceptScore W3106823914C2776623344 @default.
• W3106823914 hasConceptScore W3106823914C2776967927 @default.
• W3106823914 hasConceptScore W3106823914C2778607973 @default.
• W3106823914 hasConceptScore W3106823914C2780459521 @default.
• W3106823914 hasConceptScore W3106823914C2781069245 @default.
• W3106823914 hasConceptScore W3106823914C33923547 @default.
• W3106823914 hasConceptScore W3106823914C43617362 @default.
• W3106823914 hasConceptScore W3106823914C501593827 @default.
• W3106823914 hasConceptScore W3106823914C55493867 @default.
• W3106823914 hasConceptScore W3106823914C71924100 @default.
• W3106823914 hasConceptScore W3106823914C98274493 @default.
• W3106823914 hasFunder F4320321594 @default.
• W3106823914 hasLocation W31068239141 @default.
• W3106823914 hasOpenAccess W3106823914 @default.
• W3106823914 hasPrimaryLocation W31068239141 @default.
• W3106823914 hasRelatedWork W1985603351 @default.
• W3106823914 hasRelatedWork W2026366872 @default.
• W3106823914 hasRelatedWork W2300939807 @default.
• W3106823914 hasRelatedWork W2430040642 @default.
• W3106823914 hasRelatedWork W2610549409 @default.
• W3106823914 hasRelatedWork W2782995983 @default.
• W3106823914 hasRelatedWork W2786833888 @default.
• W3106823914 hasRelatedWork W3106823914 @default.
• W3106823914 hasRelatedWork W3195199857 @default.
• W3106823914 hasRelatedWork W4255883380 @default.

• next